![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
PharmiWeb.com: The Heart of Life Sciences on the Web
PharmiWeb.com - Global pharma news from the pharmaceutical industry, biotech, clinical research, life science & healthcare. Pharma Events Listings, Pharma Company Directory & …
Evaluate Releases 2025 Preview for Pharma Market
2025年1月7日 · Report signals industry-wide growth headlined by obesity and oncology therapy areas. LONDON – [7 th January 2025] – Evaluate, the leading provider of market insights for …
2025 Clinical Trials Outlook: Six industry trends to expect
2024年12月20日 · Rising costs, shifting regulations, and the surge of artificial intelligence (AI) have been hot topics in the industry this year and are trends that will continue into 2025. At …
Patient Portal Industry to Surge to USD 19.08 Billion by 2034 at a ...
2025年1月1日 · Patient Portal Industry The global patient portal industry is poised for significant growth, with its valuation expected to soar from USD 4,800.3 million in 2024 to an impressive …
2024 ABPI Code of Practice launched, with a new constitution and ...
2024年9月23日 · The Association of the British Pharmaceutical Industry (ABPI) and the Prescription Medicines Code of Practice Authority (PMCPA) have published an updated Code …
Ottimo Pharma Raises over $140 Million in Series A Financing
2024年12月19日 · Ottimo Pharma (“Ottimo”), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today announces the completion of …
Phastar Scoops Prestigious 2024 Scrip Award - PharmiWeb.com
2024年12月9日 · Phastar Scoops Prestigious 2024 Scrip Award . London, UK, and Durham (NC), US – December 9 th, 2024: Phastar, a global specialist biometrics contract research …
Neuraxpharm to further grow branded business with the …
2025年1月7日 · Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, …
AbbVie’s SKYRIZI® (risankizumab) Accepted by the S…
2025年1月13日 · AbbVie’s SKYRIZI ® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis. PRESS RELEASE …
Global Cough Suppressant Market Set for Remarkable Growth, …
2025年1月30日 · Cough Suppressant Market The global cough suppressant market is on track for significant expansion, with projections indicating a remarkable surge to a valuation of USD …